Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/17/2019 |
| Start Date: | January 2016 |
| Contact: | David Wang, MD, PhD |
| Email: | davidh.wang@va.gov |
| Phone: | 214-857-0737 |
Feasibility of Itraconazole as a Targeted Therapy for Inhibition of Hedgehog Pathway Signaling in Patients With Esophageal Cancer
The purpose of this study is to demonstrate that orally administered itraconazole, a commonly
used antifungal medication, can inhibit Hedgehog pathway signaling in patients with
esophageal cancer, including adenocarcinoma (EAC) and squamous cell carcinoma (ESCC).
used antifungal medication, can inhibit Hedgehog pathway signaling in patients with
esophageal cancer, including adenocarcinoma (EAC) and squamous cell carcinoma (ESCC).
Inclusion Criteria:
• Clinical diagnosis of esophageal cancer, including gastroesophageal junction cancer
Exclusion Criteria:
- Patients unwilling or unable to provide informed consent
- Coagulopathy that precludes safe endoscopic/surgical procedure (platelet count
<100,000/mm3, INR>1.5)
- Esophageal varices
- Comorbidity (e.g. pulmonary, cardiac, renal, or liver disease) that precludes safe
participation in the study
- QTc>450 ms
- LFT's>3xULN
- Pregnancy
- Allergy to itraconazole
- History of symptomatic congestive heart failure
We found this trial at
1
site
Dallas VA Medical Center VA North Texas Health Care System (VANTHCS) is a progressive health...
Click here to add this to my saved trials
